



## Grand Chikezie Ihesiulor<sup>1</sup>, Forbes Manson<sup>2</sup> and Udo Ahanna Ubani<sup>1\*</sup>

<sup>1</sup>Department of Optometry, Abia State University, Uturu, Nigeria

<sup>2</sup>Division of Genomic Studies, University of Manchester, England

Received: 30 May, 2018

Accepted: 15 June, 2018

Published: 18 June, 2018

\*Corresponding author: Udo Ahanna Ubani, Dept of Optometry, Abia State University, Uturu, Nigeria, Tel: +238036770850; E-mail: udoubani2000@yahoo.com

Keywords: Primary congenital glaucoma; CYP1B1 mutations; Single Nucleotide Polymorphisms

<https://www.peertechz.com>

## Research Article

# A Laboratory Study on the Molecular Basis of Primary Congenital Glaucoma

## Abstract

**Purpose:** To detect pathogenic mutations in cytochrome P450 family1 subfamily B polypeptide1 (*CYP1B1*) gene in nineteen sporadic Primary congenital glaucoma (PCG) cases and to identify patients lacking *CYP1B1* mutations.

**Methods:** *CYP1B1* exon 2 and the coding part of exon 3 of 15 participants were amplified by Polymerase chain reaction and amplicons were sequenced by Sanger sequencing. Sequencing data was analyzed to identify the gene mutations or Single Nucleotide Polymorphisms SNPs.

**Results:** Four previously reported PCG-associated *CYP1B1* mutations (c.1159G>A; p.E387K, c.230T>C; p.L77P, c.1103G>A; p.R368H and c.1568G>A; p.R523K) were found in four patients out of the 15 fully 'sequenced' patients. Also, ten previously reported Single Nucleotide Polymorphisms and two novel noncoding variants were identified.

**Conclusion:** The relatively low percentage of PCG patients having *CYP1B1* mutations (4/15=26.6%) demonstrates that other known and unknown genes may contribute to PCG pathogenesis. Lack of *CYP1B1* gene mutations in some patients stresses the need to identify other responsible candidates.

## Introduction

Primary congenital glaucoma (PCG) is a classical form of infant buphthalmos and a predominant type of congenital glaucoma [1,2]. Although, buphthalmos has been reported from the time of Hippocrates (460-377 BC), it was associated with high intraocular pressure (IOP) and vision loss in children in the middle of the eighteenth century [1,3,4]. In PCG, isolated maldevelopment of ocular drainage structures increases resistance to aqueous outflow [3,5,6]. This leads to increased IOP, optic nerve atrophy and blindness if prompt and proper diagnosis and management is not provided [4,7,8].

Infants with PCG are affected differently. However, presentation of epiphora, blepharospasm, photophobia and swollen or cloudy cornea due to high IOP, is the norm [7].

Familial, like sporadic, PCG is an autosomal recessive disease [9]. It is highly prevalent in the consanguineous and inbred Gypsy subpopulation of Slovakia. This was reported to be due to genetic drift or 'founder effect' [8,10]. In non Gypsy populations, PCG may be inherited in a multifactorial fashion [11].

Although the genetic component of PCG is debatable, 4 chromosomal loci has been mapped including, GLAUCOMA

3, PRIMARY CONGENITAL, A (GLC3A on 2p22.2 locus; OMIM 231300), GLC3B (1p36.2-p36.1; OMIM 600975), GLC3C (14q24.2; OMIM 601771) and GLC3D on 14q24.3 locus (OMIM 613086).

Recently, PCG phenotype was associated with mutations in cytochrome P450 family 1subfamily B polypeptide 1 (*CYP1B1*) gene on the 2p21 locus, gene symbol GLC3A (OMIM #231300) and Latent transforming growth factor beta-binding protein 2 (*LTBP2*) gene (GLC3D; OMIM 602091) [8]. The genes associated with GLC3B and GLC3C are not yet known [12].

*CYP1B1* gene analysis is the focus of this study. *CYP1B1* gene (Ensembl transcript ESNT00000260630) is a three-exon gene in which only exons 2 and part of 3 are translated [9]. It encodes a 543-amino-acid 'drug metabolizing' protein or enzyme involved in early anterior chamber angle development [13]. Mutations in *CYP1B1* have also been implicated in other anterior segment dysgenesis (ASD) syndromes [14]. The molecular role of *CYP1B1* gene in the pathophysiology of PCG is not fully understood [8]. This study identifies unrelated PCG subjects that have or lack *CYP1B1* mutations by screening the coding exons of the *CYP1B1* gene using direct sequencing procedures. Patients having no disease-causing *CYP1B1* alleles were noted for exome sequencing to find out other genetic factors involved in PCG pathogenesis [9].

## Materials and Methods

### Participants

Informed consent was obtained from the parents or responsible guardians of the subjects. The probands and their immediate families were questioned on their past medical history and examined at the hospital. Reviewing the eye charts from their respective eye physicians helped confirm their visual function. The inclusion criteria were intraocular pressure  $\geq 21$ mmHg in the first years of life, the presence of cornea oedema, scar, or Haab striae or an ocular history consistent with infantile glaucoma. The presence of enlarged globe in their teens or adulthood suggests a history of congenital glaucoma in the first few years of life. Other clinical signs were examined using portable slit lamp and direct ophthalmoscope.

### Congenital glaucoma CYP1B1 mutations (Table 1)

The study did not report the individual visual acuity, visual field and intraocular pressure of the patients.

### DNA quantification and quality assessment

In order to determine the concentration and quality of extracted DNA (patient samples), the Nanodrop 8000 (Thermo Scientific) was used to obtain the absorbance of the DNA samples at 260nm;  $A_{260}=1$  was noted as the equivalent to 50ng/ml for double stranded DNA. The Nanodrop machine was 'blanked' initially by adding of nuclease-free water 1 $\mu$ l (dH<sub>2</sub>O) onto the tip at the base of the spectrophotometer. The concentration and 260/280 values were noted (not shown).

**Table 1:** Congenital Glaucoma CYP1B1 Mutations (JH, TC, HZ, MF, BY are patient's name code, lab no. Laboratory number. DOB; Date of Birth, Homo; Homozygous, Het; heterozygous)

Patient	Mutation	Homo/Het
JH DOB 20/8/90 MG55312 (lab no. 11005694 & 067246)	p.E387K (rs55989760)	Homo
TC DOB 25/12/10 M11/003053 (lab no. 11000358)	p.R368H (rs28936414) p.L77P(CM000136)	Het Het
HZ DOB 16/9/08 MG69428 (lab no. 10004412)	p.R368H (rs28936414)	Homo
MF DOB 7/11/08 E08/16439 (lab no. 089365)	p.E387K(rs55989760)	Homo
BY DOB 9/3/04 SP04/3021 (lab no. 041104)	p.R523T (CM066028)	Het (missing 2 <sup>nd</sup> mutation)

A 260/280 absorbance ratio of  $\geq 1.8$  was considered a better amount of purity for DNA samples. Samples with concentration of more than 100ng/ $\mu$ l were diluted properly with dH<sub>2</sub>O to make 100ng/ $\mu$ l concentration.

The DNA samples (in 100ng/ $\mu$ l concentrations) were spun down for 3–5 secs using Minispin at a speed of 2000rpm to prevent DNA from being shattered.

### Designing primers

In order to design primers of the CYP1B1 gene (DNA target), the following databases were used; ensembl; a massive database/genome browser, primer3plus and reverse complement.

Human CYP1B1 (ENST00000260630) gene sequence was obtained from ensembl. Oligonucleotide sequences were synthesized by Eurofins MWG Operon.

Primers were designed to include exons and a minimum of 50 base pairs (bp) of introns for desired sequence to be completely amplified.

### Polymerase chain reaction (PCR) optimization

The best conditions for PCR were determined using gradient PCR. Primers were hydrated with a given volume of dH<sub>2</sub>O (Table 2) [15,16] (Acharya et al. 2006), and vortexed for 5–7 secs for uniform mixing of primers. Concentration varied between 5 and 10 pmol/ $\mu$ l. For a 10 pmol/ $\mu$ l concentration, 90 $\mu$ l of dH<sub>2</sub>O was added to 10 $\mu$ l of primers. The 'master mix' tubes contained; Reddy mix (NEB or Promega): 12.5 $\mu$ l x 14 = 175 $\mu$ l; Control DNA: 1.5  $\mu$ l x 14 = 21 $\mu$ l; dH<sub>2</sub>O: 6.5 $\mu$ l x 14 = 91  $\mu$ l; (Dimethyl sulfoxide) DMSO: 2.5  $\mu$ l x 14 = 35 $\mu$ l; Total 23 $\mu$ l x 14 = 322 $\mu$ l

The different proportions were multiplied by 14 (see above) to account for pipette error. DMSO was added (for F1R1 primers only) to prevent formation of spurious secondary structures. The Promega (GoTaq<sup>®</sup> Green Master mix) contains bacterially derived Taq polymerase 2 X Green GoTaq<sup>®</sup> Reaction buffer (pH 8.5), 400 $\mu$ M dATP, 400 $\mu$ M dGTP, 400 $\mu$ M dCTP, 400 $\mu$ M dTTP and 3mM MgCl<sub>2</sub>. The New England Biolabs (NEB) (OneTaq quick load, 2X MM w/std buffer MO486S) contains dNTPs, MgCl<sub>2</sub>, buffer components and stabilizers. The NEB was used due to less smearing compared to Promega. PCR was performed under appropriate conditions and according to manufacturer's guideline.

**Table 2:** Mutations in 5 patients

Patient ID	Nucleotide change	Amino acid change	rs number	EXON	Homozygous or heterozygous	References
JH5	c.1159G>A	p.E387K	<b>rs55989760</b> (CM980502)	3	Homozygous	[15]
TC7	c.230T>C + c.1103G>A	p.L77P + p.R368H	CM000136, rs28936414 (CM000137)	2,3	Compound heterozygous	[16]
HZ9	c.1103G>A	p.R368H	rs28936414	3	Homozygous	[16]
MF10	c.1159G>A	p.E387K	<b>rs55989760</b> (CM980502)	3	Homozygous	[15]
BY17	c.1568G>A	p.R523K	<b>CM066028</b>	3	Heterozygous	(Acharya et al. 2006)

Compound heterozygous or homozygous states, their reference SNP (rs) or CM numbers and the exons where they were identified

## Agarose gel electrophoresis

1% (w/v) agarose gel concentration was used throughout the study.


Gels were made with 1g of agarose powder (molecular grade) introduced into 100ml of 1x TAE (980ml of dH<sub>2</sub>O + 20ml of TAE buffer) buffer in a conical flask. After swirling gently, agarose-TAE mixture was heated for 2mins until the liquid was clear and the powder had dissolved completely. After cooling it slightly, 10 $\mu$ l SafeView (NBS Biologicals) was added. The SafeView dye is safer (less harmful) and stains DNA effectively to allow its visualization within the Agarose gel. After swirling gently and pouring the gel into the mold, a comb was placed in the second groove of the mold. After 20-30 minutes of gel setting, the combs were removed and the tray and gel were introduced into the electrophoresis tank containing sufficient 1 x TAE buffer. 5 $\mu$ l appropriately sized DNA ladder (hyperladder1 or 100bp #3231S) was loaded with pipette into the first well. 5 $\mu$ l of each amplicon was then loaded into the remaining wells carefully. Gels were electrophoresed at 100V voltage, 400Amps for 20 - 60 mins.

After electrophoresis, the gel was visualized to show the size (length) of the amplicon. This was carried out by UV-transillumination (Fluorchem imager) and an integrated camera was used to capture the images (Figure 1).

## PCR amplification

In order to efficiently amplify the desired target DNA, a standard protocol was used in all reactions. Standard 25 $\mu$ l PCR reactions contained 12.5 $\mu$ l reddy mix (NEB), 2.5 $\mu$ l DMSO, 7 $\mu$ l dH<sub>2</sub>O, 1 $\mu$ l forward primer, 1 $\mu$ l reverse primer (Invitrogen) and 1 $\mu$ l DNA template.

After PCR optimization, the right T<sub>m</sub> for Primer F1R1 and F3R3 were determined as 55 $^{\circ}$ C and 56 $^{\circ}$ C respectively. \*Taq DNA polymerase extends the target strand at a rate of approximately 1kb per minute. A negative control (containing 1 $\mu$ l of dH<sub>2</sub>O instead of DNA) was also incorporated while setting up PCR reactions.



**Figure 1:** Gel image of Polymerase chain reaction optimization. NEB and Promega stands for the two different 'reddy mixes' used, with forward (F1) and reverse (R1) primers (Exon 2). DNA Hyperladder1 on extreme end, NEB on left set of bands and Promega on the right. The bands are lined between 1000 and 1500bp length. Annealing temperatures 50, 51, 52, 53, 55, 56 $^{\circ}$ C are shown.

## PCR products purification/cleaning

PCR plate reactions were purified on Agencourt AMPure XP magnetic beads (Beckman Coulter, High Wycombe) using a Beckman Coulter Biomek NX robot (Beckman Coulter, High Wycombe). Individual PCR amplicons were purified using Montage spin columns (Millipore Ltd, Watford) according to the manufacturer's instruction.

## Capillary- electrophoresis based chain-termination sanger sequencing

Taq polymerase enzyme, deoxynucleotide triphosphates (dNTPs) and fluorescently-labelled, chain-terminating dideoxynucleotridiphosphatase (ddNTP) were used in standard proportions. Purification of the reaction is carried out to eliminate the unincorporated ddNTPs [17].

In this study, the 10  $\mu$ l sequencing reaction (master mix) was set up skirted well (PCr) plates with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). it contained 0.25  $\mu$ l BigDye v3.1, 1.875  $\mu$ l Sequencing buffer, 5.375 $\mu$ l dH<sub>2</sub>O $\pm$ 0.5 $\mu$ l, 1-1.5 $\mu$ l of the AMPure purified amplicons, 1 $\mu$ l each of forward or reverse primer (in different rows). After mounting on the thermocycler (Verti 96 well, AB), the following conditions for sequencing were used; 96 $^{\circ}$ C for 2mins, 96 $^{\circ}$ C for 10sec, 55 $^{\circ}$ C for 20 secs, 60 $^{\circ}$ C for 4 mins, 8 $^{\circ}$ C for 10mins, 4 $^{\circ}$ C hold for infinity.

## Purification of sequencing reactions

In order to remove the unincorporated dye terminator, Agencourt CleanSEQ paramagnetic bead solution (Beckman Coulter) and Beckman Coulter Biomek NX robotics were used. Multichannel pipette was used to introduce 5 $\mu$ l of CleanSEQ beads into skirted well (PCR tubes containing the sequencing product). The purification procedure was performed according to manufacturer's guideline.

## Sanger sequencing analysis

Two ABI files (sequence traces) for each patient, were created and named forward and reverse primer (for example JH5 EXON 2F.abi and JH5 EXON 2R.abi respectively). These files, and the reference sequence (*CYP1B1*) obtained from ensemble (ENST00000260630), were uploaded into the GeneScreen program.

The variants (boxes/cells) were edited and the chromatogram displayed was observed. Confirmed variants occurred in both forward and reverse reads. Strong peaks in the chromatogram were only regarded as real sequence changes. After analysis, samples with poor results were repeated. 5-10 nucleotides including variant identified were manually copied and matched on the cDNA sequence from ensembl. The number (cDNA position) was noted. Reference SNP (rs) number and other information such as chromosomal location were obtained using ensemble or Exome Variant Server (EVS).

The staden program helps to efficiently analyse sequences and identify variants/ mutations in DNA sequence. The Staden Pregap4.1.4b1 package was used to align the trace

files to the desired reference database. First, the *CYP1B1* (ENST00000260630) gene sequence obtained from UCSC genome browser was saved in a text file and uploaded to the Staden Pregap4.1.4b1 package. Then the Staden Gap package helped in analysing the contig (trace sequence) and comparing it with a known normal control (cell line DNA).

## Results

### *CYP1B1* mutational analysis

Exons 2 and 3 were (Polymerase chain reaction) PCR-amplified and sequenced for each patient as described in the Materials and Methods. Sequence files were read with either the GeneScreen or Staden programs. One patient DNA (sample AK1) failed to give readable sequence (in both exons) despite multiple attempts. 15 out of 19 patients had both exons fully sequenced (Figure 1).

In tables 1,3 non-synonymous mutations were identified in five probands. In one patient only a single mutation was found meaning that the pick-up rate for *CYP1B1* mutation being pathogenic in this panel of 15 'fully sequenced' patients was 4/15 (26.67 %). All 5 mutations had been previously reported. Four (75%) of these mutations were found in exon 3 while one (25%) was identified in exon2. Exon 3 was fully sequenced in all 19 patients, while exon 2 was only fully sequenced in 15.

Out of the five probands that had two mutations, three were homozygous for a *CYP1B1* mutation and one was compound heterozygous. The mutant alleles segregate with the disease in an autosomal recessive manner of inheritance [9,18]. Mutation c.1159G>A, a nucleotide change at cDNA position 1159 of the *CYP1B1* gene sequence is the most prevalent homozygous mutation found in two patients (Table 2) [15,16] (Acharya et al. 2006).

### Single nucleotide polymorphisms (SNP) analyses

Sequencing of 19 unrelated probands with PCG detected 12 SNPs which included four intronic variants (two in intron 1 and two in intron 2), five variants in exon 2, and 3 variants in exon 3 (Table 2) [15,16] (Acharya et al. 2006). All SNPs identified in intron1 and protein coding exons 2 and 3 have been previously reported in dbSNP, while the changes found in intron 2 are novel to the best of our knowledge (Table 2) [15,16] (Acharya et al. 2006). Intronic variant c.1043+75 t>g, was the most frequent intronic change occurring in 18/19 patients, followed by intronic change c.-1-12C>T found in 8/19 patients, and c.-1-14C>T and c.1043+84a>c, each in 1/19 patient.

The most frequent exon 3variants were c.1294G>C and c.1347T>C which were each found in 16/19 patients, followed by c.1358A>G which was present in 6/19 patients.

In exon 2, c.142C>G was the most frequent SNP and was found in 9/16 patients. This was followed by c.355G>T (7/19) and c.777C>T, c.729G>C and c.331G>C (all in 1/19). From the result, it could be deduced that patients who had pathogenic mutations were homozygous for c.-1-12C>T variant. However, only three of the mutant patients had this intronic change. Mutant patients, who had coding (exonic) SNPs, had them in

homozygous states except one of the compound heterozygous mutant probands (Table 4).

**Table 3:** Mutations and SNPs in 5 patients.

Patient ID	Variants	Heterozygous or homozygous	rs or CM number	exon or intron
TC7	c.230T>C p.L77P	Het	CM000136	exon 2
TC7	c.1043+75t>g	Hom	Novel	intron 2
TC7	c.1103G>A p.R368H	Het	rs28936414	exon 3
TC7	c.1294G>C p.V432L	Het	rs1056836	exon 3
TC7	c.1347T>C p.D449D	Het	rs1056837	exon 3
TC7	c.1358A>G p.N453S	Het	rs1800440	exon 3
HZ9	c.1043+75t>g	Hom	Novel	intron 2
HZ9	c.1103G>A p.R368H	Hom	rs28936414	exon 3
MF10	c.-1-12C>T	Hom	rs2617266	intron 1
MF10	c.142C>G p.R48G	Hom	rs10012	exon 2
MF10	c.1043+75t>g	Hom	Novel	intron 2
MF10	c.1159G>A p.E387K	Hom	rs55989760	exon 3
MF10	c.1294G>C p.V432L	Hom	rs1056836	exon 3
MF10	c.1347T>C p.D449D	Hom	rs1056837	exon 3
JH5	c.-1-12C>T	Hom	Novel	intron 1
JH5	c.142C>G p.R48G	Hom	rs10012	exon 2
JH5	c.355G>T p.A119S	Hom	rs1056827	exon 2
JH5	c.1043+75t>g	Hom	Novel	exon 2
JH5	c.1159G>A p.E387K	Hom	rs55989760	exon 3
JH5	c.1294G>C p.V432L	Hom	rs1056836	exon 3
JH5	c.1347T>C p.D449D	Hom	rs1056837	exon 3
BY17	c.1043+75t>g	Hom	Novel	intron 2
BY17	c.1294G>C p.V432L	Hom	rs1056836	exon 3
BY17	c.1347T>C p.D449D	Hom	rs1056837	exon 3
BY17	c.1568G>A p.R523K	Het	CM066028	exon 3

Patient ID stands for patient identification, heterozygous (Het) or homozygous (Hom), their reference SNP (rs) or CM numbers and the introns or exons where they were identified.

**Table 4:** The exonic and intronic variants with their rs (reference numbers and chromosomal locations).

Location	Nucleotide change	Amino acid change	Allele frequency (%)	Reference SNP number/
INTRON 1	c.-1-12C>T	NA	-	rs2617266
INTRON 1	c.-1-14C>T	NA	-	rs4987134
INTRON 2	c.1043+75t>g	NA	-	Novel
INTRON 2	c.1043+84a>c	NA	-	Novel
EXON 2	c.142C>G	p.R48G	C=0.336/731	rs10012
EXON 2	c.355G>T	p.A119S	A=0.322/702	rs1056827
EXON 2	c.777C>T	p.R259=	NA	rs72481804
EXON 2	c.729G>C	p.V243=	G=0.065/142	rs9341249
EXON 2	c.331G>C	p.G111R	NA	rs72481804
EXON 3	c.1294G>C	p.V432L	C=0.387/843	rs1056836
EXON 3	c.1347T>C	p.D449=	C=0.387/843	rs1056837
EXON 3	c.1358A>G	p.N453S	C=0.099/215	rs1800440

\*purple coloured variants are novel



These four coding SNPs; R48G, A119S, V432L, N453S combined as RAVN haplotype, are inherited together as major background haplotype for identified mutations [9].

Exons are nucleic acid sequences or the expressed region of the gene, that codes for a protein. While introns are the intragenic regions or intervening sequences that do not code for proteins but are removed through (Ribonucleic Acid) RNA splicing [19] (Figure 2).

### Variants found in five PCG patients

#### Patient JH5: c.1159G>A; p.E387K

**Brief clinical details and family history:** Patient JH5 is 23 years old. Mother may have had congenital glaucoma and father has cleft palate (CLP). JH5 presented with symptoms of isolated and bilateral glaucoma (PCG). JH5 also has CLP.

Sequencing analysis shows a previously reported homozygous missense change c.1159G>A; p.E387K in exon 3 of *CYP1B1* gene. Five previously reported polymorphisms were identified in this patient (c.-1-12C>T, c.142C>G p.R48G, c.355G>T p.A119S, c.1294G>C p.V432L, c.1347T>C p.D449D) and one novel variant (c.1043+75t>g) (Figure 3).

p.E387K is a lysine to glutamine substitution that results from a homozygous 1159G>A transition. It occurs in a highly conserved region of *CYP1B1* exon 3 and affects the conserved K helix region of the *CYP1B1* molecule. Also, this mutation is a founder PCG mutation in the Gypsy subpopulation of Slovakia. Cleft palate results from mutations in Transcription factor AP2 (*TFAP2A*) gene. *TFAP2A* may contribute to anterior segment development.

#### Patient TC7: c.230T>C p.L77P; c.1103G>A p.R368H

**Brief clinical details and family history:** TC7 is 3 years old, born prematurely and presented with bilateral congenital glaucoma.


Two previously reported heterozygous missense changes c.230T>C and c.1103G>A were identified in exons 2 and 3 respectively. Three coding polymorphisms (p.N453S, p.V432L and p.D449D) and one noncoding variant (c.1043+75t>g) were identified (Figures 4,5).

#### Patient HZ9: c.1103G>A; p.R368H


**Brief clinical details and family history:** Patient HZ9 is a 5 years old child of a consanguineous union who has congenital glaucoma, dysplastic kidneys and seizures that may be syndromic. Also, this patient has done affy array but no result was given.

Sequencing analysis shows previously reported homozygous missense change c.1103G>A; p.R368H in *CYP1B1* exon 3. One novel noncoding variant (c.1043+75t>g) was also identified (Figure 6).


G>A transition at nucleotide 1103 produces an arg368-to-his (R368H) mutation found in Saudi Arabian PCG patients.



**Figure 2:** Diagrammatic representation of *CYP1B1* (Ensembl transcript ESNT00000260630) showing the 3 exons, introns and the variants identified. The length of exons 1, 2 and 3 are 345, 1044 and 3707 base pairs respectively. The coding exons are shaded blue. Mutations are shown in black boxes (above) and SNPs below.



**Figure 3:** Staden chromatogram traces of missense mutation c.1159G>A (p.E387K). The top trace shows the mutant sequence and the bottom trace is the reference wildtype sequence. Found in patients JH5 and MF10.



**Figure 4:** Staden chromatogram traces of missense mutation c.230T>C (p.L77P) in TC7. The top trace shows the mutant sequence and the bottom trace is the reference wild type sequence.

This change showed incomplete penetrance and was reported to be absent in 100 Saudi Arabian control chromosomes. Also, this mutation has been reported to encode a protein with reduced, not abolished enzymatic activity.

#### Patient MF10: c.1159G>A p.E387K

**Brief clinical details and family history:** Patient MF10 is 3 years old and presented with bilateral anterior segment dysgenesis syndrome (Peter's anomaly) manifesting as corneal clouding. This condition was present in sister and cousin, and the child is of nonconsanguineous parents.

Sequencing analysis shows previously reported homozygous missense change c.1159G>A p.E387K in *CYP1B1* exon 3. Also, results show three coding SNPs and 2 noncoding variants (Table 4).

P.E387K mutation is a founder PCG mutation in the Gypsy population as previously described in patient JH5.

**Patient BY17: c.1568G>A p.R523K**

**Brief clinical details and family history:** Patient BY17 is 9 years old that presented with congenital glaucoma, heart murmur delay and Rieger phenotype. This patient has terminal deletion of a gene on Chromosome 6 (result not shown).

Sequencing analysis showed a single heterozygous *CYP1B1* mutation on exon 3. In addition, two coding and one noncoding variant were found in this patient (Figure 7).

Congenital glaucoma in this patient was not due to *CYP1B1* gene mutation. As stated earlier, glaucoma-associated Axenfield Rieger syndrome is due to deletion of gene located in chromosome 6p25 (forkhead Box C1 gene). This is responsible for the glaucoma in this patient.

**Table 4:** The exonic and intronic variants with their rs (reference numbers and chromosomal locations).

Location	Nucleotide change	Amino acid change	Allele frequency (%)	Reference SNP number/
INTRON 1	c.-1-12C>T	NA	-	rs2617266
INTRON 1	c.-1-14C>T	NA	-	rs4987134
INTRON 2	c.1043+75t>g	NA	-	Novel
INTRON 2	c.1043+84a>c	NA	-	Novel
EXON 2	c.142C>G	p.R48G	C=0.336/731	rs10012
EXON 2	c.355G>T	p.A119S	A=0.322/702	rs1056827
EXON 2	c.777C>T	p.R259=	NA	rs72481804
EXON 2	c.729G>C	p.V243=	G=0.065/142	rs9341249
EXON 2	c.331G>C	p.G111R	NA	rs72481804
EXON 3	c.1294G>C	p.V432L	C=0.387/843	rs1056836
EXON 3	c.1347T>C	p.D449=	C=0.387/843	rs1056837
EXON 3	c.1358A>G	p.N453S	C=0.099/215	rs1800440

\*purple coloured variants are novel


**Discussion**

*CYP1B1* gene mutations are the major molecular cause of PCG [20]. PCG is a genetically heterogeneous phenotype [13]. In this research, the genetic analysis of the coding exons 2 & 3 in *CYP1B1* gene (Ensembl transcript ESNT00000260630) of 15 unrelated PCG cases is carried out. It shows that about 4 (26.67%) out of 15 probands had at least one PCG-causing mutation previously identified in scientific research. In the four patients having mutations, three had homozygous mutations while one showed compound heterozygosity.


In addition, one patient (BY17) had a single heterozygous mutation in *CYP1B1* and a terminal deletion in forkhead transcription factor gene (*FKHL 7*). The deletion in the short arm of chromosome 6 (6p25) is responsible for Axenfeld-Rieger Syndrome (ARS) and glaucoma [21]. Patient (TC7) was born prematurely. And it is known that anterior segment anomalies can be present in premature babies [22,23].

The pick-up rate (26.67%) may be because sequencing was limited to *CYP1B1* coding exons leaving the promoter or non-coding regions [8]. Other reasons could be that the PCG phenotype may be caused by mutation in other PCG-associated loci (such as *GLC3B*, *GLC3C* or *GLC3D (LTBP2)* [8]. Pathogenic mutation in the *LTBP2* gene associated with PCG has been reported in Pakistani, European Gypsy and Iranian probands [24,25]. Moreover, it has been suggested that a pathogenic mutation in *MYOC* gene may cause PCG with a *CYP1B1* mutation via a digenic mode [26]. However, this finding is not established. Mutation in other unknown genes may be responsible for PCG in the *CYP1B1* negative patients [8].


The rest fourteen patients were *CYP1B1* negative. BY17 has ARS, so can be discounted. Although exons 2 in four probands (JH5, MF10, CS15 and JL21) was not fully sequenced, homozygous pathogenic mutations were found in two (JH5 and MF 10) (Table 2) [15,16] (Acharya et al. 2006).



**Figure 5:** Staden chromatogram traces showing missense mutation c.1103G>A (p.R368H) in a heterozygous state. The top trace shows the mutant sequence and the bottom trace is the reference wildtype sequence. Found in TC7.



**Figure 6:** Staden chromatogram traces of missense mutation c.1103G>A (p.R368H) in a homozygous state. The top trace shows the mutant sequence and the bottom trace is the reference wildtype sequence. Found in patient HZ9.



**Figure 7:** GeneScreen chromatogram traces showing missense mutation c.1568G>A (p.R523T). The top trace shows the forward sequence which has the mutation (c.1568G>A) in BY17, and the bottom trace is the reverse sequence.

From our results, PCG showed allelic heterogeneity in the patients (JH5 and MF10) associated with homozygosity for 2 different *CYP1B1* mutations and on patient (TC7) showing compound heterozygosity in two distinct *CYP1B1* mutations. Allelic heterogeneity explains the molecular contribution for a uniform clinical manifestation of probands, and homozygous and compound heterozygous explains the autosomal recessive nature of PCG [15,27].

p.R368H (found in TC7 and HZ9) is a hypomorphic mutation located in the conserved core structure (CCS), J helix region of the *CYP1B1* protein [16]. This causes a decline in *CYP1B1* enzymatic activity (~20% of wild type protein) or decrease in protein stability [27]. In a study by Li et al. [20], p.R368H was mostly found in white Europeans [20].

Mutation p.E387K (found in JH5 and MF10) is most common among Slovakian Gypsies, less in caucasians (4.90%), present in Amish population and absent in Asians and middle easterners [18,20]. For effective genetic screening in PCG patients, it is necessary to find out the common and founder mutations in a given population [21].

E387K is the founder mutation that accounts for 79.63% of *CYP1B1* gene mutations [15]. The high rate of consanguinity (especially cousin to cousin marriages) and high coefficient of inbreeding in the Middle Eastern and Gypsy populations explains the high occurrence of the E387K mutation [20].

The amino acid position (Glu387) in which p.E387K mutation changes glutamic acid to lysine, is a highly conserved position in all documented species and P450 enzymes [28]. Also it's a core element located in helix K, a region suspected to be essential for proper folding and active haem binding of the *CYP1B1* enzyme [19,29].

The mutation found in patient BY17 (c.1568G>A) was previously identified in Israeli Bedouin kindred and it was stated that it obliterates the DdeI restriction site and disrupts the CYP enzyme active site found in the C-terminal region of the *CYP1B1* enzyme [27]. Bar-yoseph et al. [27], reports this variant that changes arginine to lysine in amino acid position 523 (p.R523K), was not found in 100 healthy individuals [27].

In our study, fourteen patients had no disease-associated mutations in the fully sequenced regions of the *CYP1B1* gene. This supports the report that some unidentified molecular etiology is behind the PCG in some patients [27].

Residue change from leucine (L) to Proline (P) at position 77 (p.L77P), results from c.230T>C missense mutation. This previously reported mutation (found in patient TC7) occurs in conserved position. It has been reported to be associated with PCG in Saudi families [16].

Information from this study shows that early genetic testing is pertinent to determine the carrier status of individuals and their phenotype [20]. Late presentation of PCG is associated with profound visual impairment in children [21].

Having identified *CYP1B1* negative patients, future studies can be undertaken to determine other genetic causes of PCG by whole exome sequencing of these subjects.

Furthermore, the absence of *CYP1B1* mutations in some PCG patients supports that another unidentified gene is mutated. The residual level of *CYP1B1* activity is modulated by the presence of modifier genes [9].

## Conclusions

The number of *CYP1B1* negative (11/15) probands was higher than the *CYP1B1* positive (4/15) patients. Some mutations may have been missed due to the genetic screening strategy applied. This is the first drawback of this study. Screening was not extended up to the regulatory sequences in the upstream or downstream regions in the introns although bit of introns were sequenced due to primer design [9].

The noncoding regions (including exon 1) may have the disease-related variants whereas this study screened only protein coding exons 2 and 3 of the gene [8]. For accurate genetic diagnosis of PCG, all three exons need to be sequenced [9].

Secondly, the small sample size (19) prevents conclusions to be confidently made; confirmation of result is therefore needed with larger number of subjects [20].

In conclusion, the analysis of *CYP1B1* genotypes of 19 unrelated patients is reported in this study. A relatively low proportion of our subjects (~27%) tested positive for PCG-related *CYP1B1* mutations demonstrate the need to identify other PCG-causing genes.

Exome sequencing of *CYP1B1* negative patients to detect new genes mutated in PCG.

Co-segregation analysis of other unaffected and affected family members may be carried in the future.

## References

- Mandal AK, Chakrabarti D (2011) Update on congenital glaucoma. *Indian J Ophthalmol* 59:148-57. [Link: https://tinyurl.com/y8fe3fws](https://tinyurl.com/y8fe3fws)
- Shaffer RN, Weiss DI (1970) Infantile glaucoma: diagnosis and differential diagnosis. *Congenital and Pediatric Glaucomas*. CV Mosby St. Louis.
- Ritch R, Shields MB, Krupin T (1996) *The glaucomas: glaucoma therapy*, 2<sup>nd</sup> ed. Mosby-year Book Inc.
- Anderson DR (1981) The development of the trabecular meshwork and its abnormality in primary infantile glaucoma. *Trans Am Ophthalmol Soc* 79: 458-485. [Link: https://tinyurl.com/y9qyb8ee](https://tinyurl.com/y9qyb8ee)
- deLuise VP, Anderson DR (1983) Primary infantile glaucoma (congenital glaucoma). *Surv Ophthalmol* 28: 1-19. [Link: https://tinyurl.com/yadvtdg3](https://tinyurl.com/yadvtdg3)
- Bejjani BA, Xu L, Armstrong D, Lupski JR, Reneker LW (2002) Expression Patterns of Cytochrome P4501B1 in FVB/N Mouse Eyes. *EExp Eye Res* 75: 249-257. [Link: https://tinyurl.com/ydkeepop](https://tinyurl.com/ydkeepop)
- Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, et al. (2004) Primary Congenital Glaucoma.
- Kim HJ, Suh W, Park SC, Kim CY, Park KH, et al. (2011) Mutation spectrum of *CYP1B1* and *MYOC* genes in Korean patients with primary congenital glaucoma. *Molecular vision* 17: 2093-2101. [Link: https://tinyurl.com/yaksz7x](https://tinyurl.com/yaksz7x)



9. López-Garrido MP, Medina-Trillo C, Morales L, Garcia-Feijoo J, Martínez-de-la-Casa JM, et al. (2012) Genotypes in Primary Congenital and Non dominant Juvenile Glaucoma. *Ophthalmology*.
10. Genčík A (1989) Epidemiology and genetics of primary congenital glaucoma in Slovakia. Description of a form of primary congenital glaucoma in gypsies with autosomal-recessive inheritance and complete penetrance. *Developments in ophthalmology* 16: 76-155. [Link: https://tinyurl.com/ybjzm724](https://tinyurl.com/ybjzm724)
11. Gencík A, Gencíková A, Gerinec A (1980) Genetic heterogeneity of Congenital glaucoma. *Clin Genet* 17: 241-248. [Link: https://tinyurl.com/y9aqbh82](https://tinyurl.com/y9aqbh82)
12. Kaur K, Reddy ABM, Mukhopadhyay A, Mandal AK, Hasnain SE, et al. (2005) Myocilin gene implicated in primary congenital glaucoma. *Clinical Genetics* 67: 335-340. [Link: https://tinyurl.com/ybe8aqwe](https://tinyurl.com/ybe8aqwe)
13. Stoilov I, Akarsu AN, Sarfarazi M (1997) Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. *Hum Mol Genet* 6: 641-647. [Link: https://tinyurl.com/yc6zt6a2](https://tinyurl.com/yc6zt6a2)
14. Calugaru D (2010) Mendelian molecular genetics in glaucoma. *Oftalmologia* 54: 8-20. [Link: https://tinyurl.com/ya8vju5c](https://tinyurl.com/ya8vju5c)
15. Plášilová M, Stoilov I, Sarfarazi M, Kádasi L, Feráková E, et al. (1999) Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma. *J Med Genet* 36: 290-294. [Link: https://tinyurl.com/y9sdn5lg](https://tinyurl.com/y9sdn5lg)
16. Bejjani BA, Stockton DW, Lewis RA, Tomey KF, Dueker DK, et al. (2000) Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus. *Human Molecular Genetics* 9: 367-374. [Link: https://tinyurl.com/y8jqyaly](https://tinyurl.com/y8jqyaly)
17. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proceedings of the National Academy of Sciences* 74: 5463-5467. [Link: https://tinyurl.com/ydxrsxd2](https://tinyurl.com/ydxrsxd2)
18. Martin SN, Sutherland J, Levin AV, Klose R, Priston M, et al. (2000) Molecular characterisation of congenital glaucoma in a consanguineous Canadian community: a step towards preventing glaucoma related blindness. *J Med Genet* 37: 422-427. [Link: https://tinyurl.com/yb8pwck7](https://tinyurl.com/yb8pwck7)
19. Berk AJ (2006) Discovery of RNA splicing and genes in pieces. *Proc Natl Acad Sci USA* 113: 801-805. [Link: https://tinyurl.com/ycrcycyz](https://tinyurl.com/ycrcycyz)
20. Li N, Zhou Y, Du L, Wei M, Chen X (2011) Overview of Cytochrome P450 1B1 gene mutations in patients with primary congenital glaucoma. *Experimental Eye Research* 93: 572-579. [Link: https://tinyurl.com/ya8dnvuw](https://tinyurl.com/ya8dnvuw)
21. Nishimura DY, Swiderski RE, Alward WL, Searby CC, Patil SR, et al. (1998) the forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which maps to 6p25. *Nat Genet* 19: 140-147. [Link: https://tinyurl.com/yd24tkjs](https://tinyurl.com/yd24tkjs)
22. Worst JGF (1966) *The Pathogenesis of Congenital Glaucoma*. Royal Vangorcum, Assen. Netherlands.
23. Kwitko ML (1973) *Glaucoma in Infants and Children*. Meredith Corporation, New York.
24. Ali M, McKibbin M, Booth A, Parry DA, Jain P, et al. (2009) Null Mutations in LTBP2 Cause Primary Congenital Glaucoma. *American Journal of Human Genetics* 84: 664-671. [Link: https://tinyurl.com/y7dm5rzn](https://tinyurl.com/y7dm5rzn)
25. Naroie-Nejad M, Paylakhi SH, Shojaee S, Fazlali Z, Rezaei Kanavi M, et al. (2009) Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. *Human molecular genetics* 18: 3969-3977. [Link: https://tinyurl.com/yav4kn9z](https://tinyurl.com/yav4kn9z)
26. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, et al. (2002) Digenic Inheritance of Early-Onset Glaucoma: CYP1B1, a Potential Modifier Gene. *Am J Hum Genet* 70: 448-460. [Link: https://tinyurl.com/yap795yq](https://tinyurl.com/yap795yq)
27. Bar-Yosef U, Levy J, Elbedour K, Ofir R, Carmi R, et al. (2010) Congenital Glaucoma CYP1B1 Mutations in Israeli Bedouin Kindreds. *J Glaucoma* 19: 35-38. [Link: https://tinyurl.com/ybtuynto](https://tinyurl.com/ybtuynto)
28. López-Garrido MP, Blanco-Marchite C, Sánchez-Sánchez F, López-Sánchez E, Chaqués-Alepuz V, et al. (2010) Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma. *Clin Genet* 77: 70-78. [Link: https://tinyurl.com/yc6vkhq3](https://tinyurl.com/yc6vkhq3)
29. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, et al. (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. *Am J Hum Genet* 62: 573-584. [Link: https://tinyurl.com/yc08b4z6](https://tinyurl.com/yc08b4z6)
30. Kim HS, Hong SJ, LeDoux MS, Kim KS (2001) Regulation of the tyrosine hydroxylase and dopamine β-hydroxylase genes by the transcription factor AP-2. *J Neurochem* 76: 280-294. [Link: https://tinyurl.com/ycmqhmsk](https://tinyurl.com/ycmqhmsk)
31. Ben-Zion I, Bogale A, Moore DB, Helveston EM (2010) Bilateral primary congenital glaucoma in monozygotic twins. *J Pediatr Ophthalmol Strabismus* 47: 124-126. [Link: https://tinyurl.com/yajyv2qq](https://tinyurl.com/yajyv2qq)
32. Nebert D W (1990) DRUG-METABOLISM - GROWTH SIGNAL PATHWAYS. *Nature* 347: 709-710. [Link: https://tinyurl.com/y7upjhqn](https://tinyurl.com/y7upjhqn)
33. Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. *The Lancet* 360: 1155-1162. [Link: https://tinyurl.com/y7hyx4h5](https://tinyurl.com/y7hyx4h5)
34. Schwartzman ML, Balazy M, Masferrer J, Abraham NG, McGiff JC, et al. (1987) 12 (R)-hydroxycosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na<sup>+</sup>, K<sup>+</sup>-ATPase in the cornea. *Proceedings of the National Academy of Sciences* 84: 8125-8129. [Link: https://tinyurl.com/yb8m2qug](https://tinyurl.com/yb8m2qug)
35. Kupfer C, Kaiser-Kupfer MI (1978) New hypothesis of developmental anomalies of the anterior chamber associated with glaucoma. *Transactions of the ophthalmological societies of the United Kingdom* 98:213. [Link: https://tinyurl.com/y75zq5nv](https://tinyurl.com/y75zq5nv)
36. Vincent A, Billingsley G, Priston M, Williams-Lyn D, Sutherland J, et al. (2001) Phenotypic heterogeneity of CYP1B1: mutations in a patient with Peters' anomaly. *J Med Genet* 38: 324-326. [Link: https://tinyurl.com/ybu8vnmm](https://tinyurl.com/ybu8vnmm)
37. Dimasi DP, Hewitt AW, Straga T, Pater J, MacKinnon JR, et al. (2007) Prevalence of CYP1B1 mutations in Australian patients with primary congenital glaucoma. *Clin Genet* 72: 255-260. [Link: https://tinyurl.com/ybxtjhbs](https://tinyurl.com/ybxtjhbs)
38. Stoilov IR, Costa VP, Vasconcellos JP, Melo MB, Betinjane AJ, et al. (2002) Molecular genetics of primary congenital glaucoma in Brazil. *Invest Ophthalmol Vis Sci* 43: 1820-1827. [Link: https://tinyurl.com/ycdgdrrk](https://tinyurl.com/ycdgdrrk)
39. Chavarria-Soley G, Sticht H, Akiillu E, Ingelman-Sundberg M, Pasutto F, et al. (2008) Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. *Human mutation* 29: 1147-1153. [Link: https://tinyurl.com/yb94lfje](https://tinyurl.com/yb94lfje)
40. Akarsu AN, Turacli ME, Aktan SG, Barsoum-Homsy M, Chevrette L, et al. (1996) A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region. *Human Molecular Genetics* 5:1199-1203. [Link: https://tinyurl.com/yc83c2nn](https://tinyurl.com/yc83c2nn)
41. Stoilov IR, Sarfarazi M (2002) The Third Genetic Locus (GLC3C) for Primary Congenital Glaucoma (PCG) Maps to Chromosome 14q24.3. *ARVO*





Annual Meeting Abstract Search and Program Planner 43: 3015. [Link: https://tinyurl.com/y8gjn9nh](https://tinyurl.com/y8gjn9nh)

42. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, et al. (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. *J Biol Chem* 269: 13092-13099. [Link: https://tinyurl.com/yd2d2tny](https://tinyurl.com/yd2d2tny)

43. Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, et al. (1996) Isolation and characterization of the human cytochrome P450 CYP1B1 gene. *J Biol Chem* 271: 28324-28330. [Link: https://tinyurl.com/y9cpcxwp](https://tinyurl.com/y9cpcxwp)

44. Graham-Lorence SE, Peterson JA (1996) Structural alignments of P450s and extrapolations to the unknown. *Methods in enzymology* 272: 315-326. [Link: https://tinyurl.com/yaftokf2](https://tinyurl.com/yaftokf2)

**Copyright:** © 2018 Ihesiulor GC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Citation:** Ihesiulor GC, Manson F, Ubani UA (2018) A Laboratory Study on the Molecular Basis of Primary Congenital Glaucoma. *J Clin Res Ophthalmol* 5(1): 014-022. DOI: <http://doi.org/10.17352/2455-1414.000049>